The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Bimekizumab for scalp, nail, and palmoplantar psoriasis: 2-year pooled analysis
|
Plaque psoriasis impacts areas such as scalp, nails, palms, and soles leading to inferior patient QoL. Merola et al. published the results of a 2-year pooled analysis from five phase III/IIIb trials (NCT03370133, NCT03410992, NCT03412747, NCT03598790, and NCT03536884) evaluating the efficacy of bimekizumab in 1,107 patients with moderate-to-severe plaque psoriasis in Dermatology and Therapy.1 |
| Key learnings |
| Rapid scalp clearance was achieved by 83.7% at Week 16 among patients with scalp IGA ≥3 at baseline (n = 821). Responses were maintained in 86.4% of patients at Y1 and 85.9% of patients at Y2. |
| Among patients with mNAPSI >10 at baseline, rates of complete nail clearance increased to 63.4% and 69.1% at the end of Y1 and remained stable at 68.5% and 69.9% at Y2 in the bimekizumab total and Q4W/Q8W groups, respectively. |
| At Week 16, 87.4% of patients in the bimekizumab total group achieved palmoplantar clearance. High rates of complete response were sustained at Y1 and Y2 in 88.3% and 89.8% and 94.2% and 88.5% of patients in bimekizumab total and Q4W/Q8W groups, respectively. |
| These results show that bimekizumab was effective and provided sustained responses over 2 years in high-impact areas in patients with moderate-to-severe plaque psoriasis. |
Abbreviations: IGA, Investigator’s Global Assessment; mNAPSI, modified Nail Psoriasis Severity Index; Q4W, every 4 weeks; Q8W, every 8 weeks; QoL, quality of life; Y1, Year; Y2, Year 2.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
